IPCALAB

Overview & Business

Overview & Business Ipca Laboratories is an Indian pharmaceutical company engaged in manufacturing and marketing formulations and APIs (active pharmaceutical ingredients). It operates globally, exporting to many countries. In R&D, it focuses on new process routes, analytical research, biosimilar development, and drug discovery. Its R&D centers are recognized by the Indian government. It has capabilities in chemical and biotechnological research, moving from small molecules toward biologics / biosimilars. Recent Developments & News Biosimilar collaboration Ipca has entered into a technology transfer & joint development agreement with BioSimilar Sciences (BSS) for a monoclonal antibody biosimilar aimed at cancer/autoimmune diseases. Under this deal, Ipca handles late-stage development; BSS does manufacturing & supply. The expected launch is around 2027. Board / result announcements The board is scheduled to meet on August 11, 2025, to consider unaudited standalone & consolidated results. Also, the company holds its Annual General Meeting (AGM) on the same date. Regulatory / approval updates One of its formulation manufacturing units (in the SEZ, Indore) has received UK-MHRA (Medicines & Healthcare products Regulatory Agency) approval, helping boost credibility in regulated markets. Analyst / market view In Q1 FY26, Ipca reported an EBITDA growth of ~35% year-on-year. Management has reiterated a guidance of ~9–10% revenue growth for FY26, though margins are pressured by price erosion and one-off items.